Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.
STATE OF NEW YORK
________________________________________________________________________
10260
IN SENATE
May 8, 2026
___________
Introduced by Sen. WEBB -- read twice and ordered printed, and when
printed to be committed to the Committee on Health
AN ACT to amend the public health law, in relation to newborn screening
for CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases
The People of the State of New York, represented in Senate and Assem-bly, do enact as follows:
1 Section 1. Subdivision 1 of section 2500-a of the public health law is
2 amended by adding five new paragraphs (l), (m), (n), (o) and (p) to read
3 as follows:
4 (l) Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2).
5 (m) Mucopolysaccharidosis type IVA (MPS IVA).
6 (n) Mucopolysaccharidosis type VI (MPS VI).
7 (o) Mucopolysaccharidosis type VII (MPS VII).
8 (p) Fabry.
9 § 2. Section 2500-a of the public health law is amended by adding a
10 new subdivision 4 to read as follows:
11 4. The commissioner shall ensure tests are made available for all
12 diseases and conditions designated pursuant to paragraphs (l), (m), (n),
13 (o) and (p) of subdivision one of this section within twelve months of
14 the effective date of such paragraphs.
15 § 3. This act shall take effect immediately.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[] is old law to be omitted.
LBD15047-03-6
